Principal Investigator
Jaime Merchan
Enrollment Status
Open
Clinical Trial ID
Institutional Protocol #
20241053
Clinical Trial Summary
A Multicenter First-in-human Dose Escalation and Optimization Phase I/IIa Trial to Investigate Safety, Tolerability, Pharmacokinetics, and Efficacy of the 5T4 Antibody-Drug Conjugate TUB-030 in Patients with Advanced Solid Tumors (5-STAR 1-01)
Phase
Phase I/II
Funding Agency/Sponsor
Industrial
Disease
Prostate, Bladder, and Kidney Cancers
Contact Information
Phone Number
+1 (407) 7659589